Evaluation of nanoparticle tracking analysis (NTA) in the characterization of therapeutic antibodies and seasonal influenza vaccines: pros and cons

Nanoparticle tracking analysis (NTA) is a relatively new technique for the size characterization of particles between 40 and 1000nm. Recent studies have shown an increasing interest in NTA as a complementary technique in the field of pharmaceutical sciences. In this review, the applications of NTA f...

Full description

Saved in:
Bibliographic Details
Published in:Journal of drug delivery science and technology 2012, Vol.22 (5), p.427-433
Main Authors: Patois, E., Capelle, M.A.H., Palais, C., Gurny, R., Arvinte, T.
Format: Article
Language:English
Subjects:
Cell culture
Drug delivery
Field-flow fractionation
imaging
Influenza
Influenza vaccines
Light scattering
mAb
Monoclonal antibodies
Nanoparticle tracking analysis
nanoparticles
Particle size distribution
Pharmaceuticals
Size distribution
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nanoparticle tracking analysis (NTA) is a relatively new technique for the size characterization of particles between 40 and 1000nm. Recent studies have shown an increasing interest in NTA as a complementary technique in the field of pharmaceutical sciences. In this review, the applications of NTA for the characterization of biopharmaceuticals are discussed, and procedures are proposed for the determination of size distributions. The size distribution of monoclonal antibody (mAb) aggregates in samples produced from different clones in the presence of cell culture medium is presented as an example in addition to that of seasonal influenza vaccines. This review also discusses techniques such as fluorescence microscopy with Nile Red staining, micro-flow imaging, 90° light scattering, and flow field-flow fractionation (FFF) and concludes that NTA is a suitable technique for a wide range of applications in the field of biopharmaceuticals.
ISSN:1773-2247
DOI:10.1016/S1773-2247(12)50069-9